Top 100 medical and healthcare startups in UK
Nov 16, 2025
Like
16
1
Funding: $70M
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
2
Funding: $21M
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
3
Funding: $50M
SheMed is transforming women's health by offering accessible and personalized test-to-treat solutions designed particularly for women.
SheMed is transforming women's health by offering accessible and personalized test-to-treat solutions designed particularly for women.
4
Funding: $421.2M
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
5
Funding: $169.2M
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
6
Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
7
Funding: £27M
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
8
Funding: $11.4M
Genflow Biosciences is a biotech dedicated to discovering and advancing new therapeutic approaches to halt or slow the ageing process for longer, healthier lives. Genflow Biosciences’ lead compound, GF-1002, operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
Genflow Biosciences is a biotech dedicated to discovering and advancing new therapeutic approaches to halt or slow the ageing process for longer, healthier lives. Genflow Biosciences’ lead compound, GF-1002, operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
9
Funding: £4.3M
Edinburgh Biosciences offers design, development, manufacture, sales, and support of optoelectronic components for biomedical markets.
Edinburgh Biosciences offers design, development, manufacture, sales, and support of optoelectronic components for biomedical markets.
10
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
11
Funding: $1.3B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
12
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
13
Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
14
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
15
Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
16
Funding: $601.7M
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
17
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
18
Funding: $430M
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
19
Funding: $411.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
20
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
